Pfizer | PFE - Заемный капитал





Заемный капитал Изменить Дата
AbbVie USD 58.94B 4.03B 2025-12
Abbott USD 29.64B 19.74B 2026-03
ALKERMES USD 1.48B 1.2B 2026-03
Amgen USD 51.89B 1.88B 2026-03
AstraZeneca USD 25.96B 177M 2026-03
Bayer EUR 30.68B 1.15B 2026-03
Biogen USD 6.29B 1.7M 2026-03
Bristol-Myers Squibb USD 42.15B 698M 2026-03
Coherus Biosciences USD 51.08M 496K 2025-12
Drreddys Laboratories INR 12.2B 12.07B 2026-03
Eli Lilly USD 39.37B 1.5B 2026-03
Gilead Sciences USD 20.86B 1.27B 2026-03
GlaxoSmithKline GBP 14.01B 696M 2026-03
Glaxosmithkline GBP 18.53B 1.29B 2026-03
J&J USD 37.53B 1.91B 2026-03
Medtronic USD 27.88B 255M 2025-12
Merck USD 46.67B 77M 2026-03
Neurocrine Biosciences USD 169.5M 500K 2023-03
Novartis USD 37.45B 7.86B 2026-03
Novartis USD 37.45B 7.86B 2026-03
Pacira USD 367.66M 4.53M 2026-03
Perrigo USD 3.62B 17.5M 2026-03
Pfizer USD 60.57B 1.08B 2026-03
Phibro Animal Health USD 597.68M 5.92M 2026-03
Prestige Brands USD 1.01B 40.28M 2026-03
Regeneron Pharmaceuticals USD 1.99B 719.7M 2026-03
Roche Holding CHF 27.43B 966M 2025-12
Sanofi EUR 13.84B 1.88B 2026-03
Sanofi EUR 12.3B 3.42B 2026-03
Vertex Pharmaceuticals USD 106.7M 4.7M 2025-12
Zoetis USD 9.04B 3M 2026-03